Member Info for dafad

more news on the way imho

tegumen PLC Unsecured Loan Facility Agreement with Cellulac
15/06/2020 7:01am
UK Regulatory (RNS & others)

Integumen (LSE:SKIN)
Intraday Stock Chart

Monday 15 June 2020

TIDMSKIN
RNS Number : 8861P
Integumen PLC
15 June 2020
AIM share code: SKIN
Integumen PLC
("Integumen" or "Company")
Unsecured Loan Facility Agreement with Cellulac Limited
The Company has today announced its audited results for the year ended 31 December 2019. As reported, 2019 was another transformational year for Integumen. Building on an already successful business model, better than expected sales growth from higher revenues per client, lower management overhead from disposal of non-performing assets, and expansion into new areas requiring an increase of both employees and capacity, have set the business on a strong footing for 2020. At the year end (31 December 2019) the Company had cash balances of GBP1.2m. Managing working capital while rapidly growing is a delicate balance. Since the year end there have been the following developments:
-- Labskin laboratories, York, UK, increased size from 3,000 to 6,000 square feet[i].
o Working capital to support GBP2m confirmed orders in by the end of March.
o Investment of GBP250,000 to ramp-up production of Modern Water's reagent bacteria under 3-year agreement.
-- New employees joined the Company during the COVID19 lockdown due to increased demand.
-- Doubling of production capacity of Modern Water's reagent bacteria[ii]
-- Miniaturisation of RAWTest AI equipment for SARS-CoV-2[iii] in wastewater and dental clinics at University of Aberdeen containment level 3 for development.
In order to give the Company some additional flexibility to manage this growth, the Board has entered into a GBP400,000 loan facility ("Loan") with Cellulac Limited ("Cellulac"); the principal terms of the Loan are as follows:

Let's hope so

I meant the to put june 15th!

Can you put me down for june 14th please

Perfectly sound reason they PAUSED copd trials
this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial,

Update on SNG001 Phase II trial in COPD
Synairgen is now close to completing a Phase II study in chronic obstructive pulmonary disease (COPD) patients with confirmed respiratory viral infections and pre-existing significant impairment of lung function. With 109 out of a target 120 participants already dosed, this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial, who will be at the forefront in dealing with patients suffering from COVID-19. We are currently exploring ways to adapt the trial to enable patients in the pre-treatment pool to be dosed if they become infected with SARS-CoV-2.

Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.

Going back up

I'm afraid they were sells as per todays Rns

From ITM trading update out today,looks good in terms of climate change mitigatio
n for us

Dr Graham Cooley, CEO, ITM Power plc, commented: "The emerging trends in different industrial sectors, together with increasing acceptance by governments around the world that green hydrogen is an essential vector to achieve their carbon reduction commitments, bode very well for the electrolysis market. Against this background, ITM Power with partner Linde is very well placed to capitalise on the major opportunities we expect to arise from the continuing drive towards climate change mitigation."

tim000

5 Jun '20 - 08:20 - 758 of 760

0  4 0

Apologies if either of these points have already been made. First, Billingham will entail connection to Northern Powergrid's infrastructure. Northern Powergrid is owned by Berkshire Hathaway Energy, which in turn is 90% owned by Warren Buffett's Berkshire Hathaway. I think that's interesting! Second, Altair can't convert its CLN if that entails breaching the 30% shareholding ceiling. It currently has capacity to convert a portion of the loan at 0.375p per share into 63 million shares, without exceeding 30%. If it waits much longer, it will have to pay a 10% discount to the current share price for conversion, which might significantly exceed 0.375p. (That assumes it is allowed to convert a portion of the CLN.) So it will be interesting to see if it decides to convert some of the CLN imminently. It will only be able to convert the entire CLN once the share price hits 1.85p

Gerard J Brandon

@gjbrandon
·
51m

Former Chief UK Medical Officer Dame Sally Davies on Sky News speak g on ##COVID19 "We don't know whether there will be a large 2nd wave or whether there will be lots of little waves until we are immune." That is why there is a #race2realtime with wastewater detecti

I wonder how todays meetings went?

primary bid

Interesting Rns just out by KDNC

.

eel Hunt is a specialist investment bank focused on corporate broking, advisory, research, sales and trading and has been engaged to provide guidance to the Directors on strategic initiatives including selecting an appropriate reverse takeover ('RTO') candidate.
The Company is in negotiations with several RTO candidates in the healthcare sector. The Covid-19 pandemic has created new opportunities for companies in the healthcare sector and the RTO candidates under current consideration are exploring ways in which their therapeutic product candidates may help patients with Covid-19. At this stage, there can be no assurance that the Company will be able to agree terms with any RTO candidates or complete a RTO transaction.

Motif Bio (LSE:MTFB)
Intraday Stock Chart

Monday 1 June 2020

TIDMMTFB
RNS Number : 4247O
Motif Bio PLC
01 June 2020
Motif Bio plc
("Motif Bio" or the "Company")
Business Update
&
Appointment of Strategic Adviser
Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces a business update and the appointment of Peel Hunt LLP ("Peel Hunt") as strategic adviser to the Company. Peel Hunt is a specialist investment bank focused on corporate broking, advisory, research, sales and trading and has been engaged to provide guidance to the Directors on strategic initiatives including selecting an appropriate reverse takeover ('RTO') candidate.
The Company is in negotiations with several RTO candidates in the healthcare sector. The Covid-19 pandemic has created new opportunities for companies in the healthcare sector and the RTO candidates under current consideration are exploring ways in which their therapeutic product candidates may help patients with Covid-19. At this stage, there can be no assurance that the Company will be able to agree terms with any RTO candidates or complete a RTO transaction.
Following its reclassification as an AIM Rule 15 cash shell in January 2020, the Company is required to make an acquisition which constitutes a reverse takeover under the AIM Rules by 28 July 2020, failing which the Company's ordinary shares would be suspended from trading on AIM pursuant to AIM Rule 40. The Company's admission to trading on AIM would then be cancelled six months from the date of suspension, should the reason for the suspension not have been rectified.
As previously disclosed, following the recent placing to raise gross proceeds of GBP650,000 the Company has sufficient working capital until February 2021 and the Directors remain focused on completing a RTO prior to that time.
Jonathan Gold, President and Chief Business Officer of Motif Bio, said: "Following the recent fundraise we are pleased to be in a position where we have several options to evaluate. We are currently working with our advisers to identify the most appropriate RTO candidate for the Company and look forward to providing our shareholders with further updates as appropriate."
The person responsible for the release of this announcement on behalf of Motif Bio is Jonathan Gold, President and Chief Business Officer.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information please contact:

it would be before TW started mouthing off

I have noted many times before that SP Angel is so utterly desperate for clients to fund the coke and hookers bills that it will act for any corporate even a brazen fraud like MySquar (MYSQ). It is morally bankrupt and, without doubt, London's worst Nomad. As such with WH Ireland have quit as Nomad to Eurasia Mining (EUA) over the lying and other matters there was only one Nomad to go to, only one that would act for a company like this.

Are they talking about Tom AND co!!!

who as a qualified lawyer and M&A practitioner will strengthen our execution team, while we are making progress on our M&A plans."

Https://en.wikipedia.org/wiki/Iain_Rawlinson